Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) reports on events occurring through August 22, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California. The filing addresses the resolution of a listing compliance issue with The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes and Events
- Listing Non-Compliance: On May 14, 2025, Nasdaq notified the Company of non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) due to a closing bid price below $1.00 for 30 consecutive business days.
- Delisting Risk: Due to a prior reverse stock split within one year, the Company faced immediate suspension and potential delisting starting May 23, 2025.
- Compliance Extension: A hearing request stayed the suspension. On July 2, 2025, the Nasdaq Panel granted an exception until August 14, 2025, to demonstrate compliance.
- Resolution: On August 22, 2025, Nasdaq confirmed the Company has regained compliance with the Minimum Bid Price Requirement, closing the matter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future operations, or discussion of new risks beyond the resolved listing issue. The primary contingency addressed was the potential delisting from the Nasdaq Capital Market, which has been successfully mitigated.
Investor Verification Checklist
- Verify the current trading price of DRMA common stock to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the continued listing status of both Common Stock (DRMA) and Warrants (DRMAW) on The Nasdaq Capital Market.
- Review subsequent filings for any new compliance notices or financial updates, as this 8-K does not contain financial data.